Stockwatch: The Biotech Upgrade Cycle
This article was originally published in Scrip
One of the positive investment attributes of the technology sector is the upgrade cycle. The continual advancements that result in faster speed, longer battery life and more features translate into consumer demand that justifies discarding last year's phone in favour of this year's model. With so many biotech companies coming to the market in the current IPO window, many are developing drugs that are upgrades of those already on the market.
You may also be interested in...
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.